Cargando…
CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer’s disease
OBJECTIVE: There is still an urgent need for supportive minimally invasive and cost-effective biomarkers for early diagnosis of Alzheimer’s disease (AD). Previous work in our lab has identified Kallikrein-8 (KLK8) as a potential candidate since it shows an excessive increase in human brain in precli...
Autores principales: | Teuber-Hanselmann, Sarah, Rekowski, Jan, Vogelgsang, Jonathan, von Arnim, Christine, Reetz, Kathrin, Stang, Andreas, Jöckel, Karl-Heinz, Wiltfang, Jens, Esselmann, Herrmann, Otto, Markus, Tumani, Hayrettin, Herring, Arne, Keyvani, Kathy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6952834/ https://www.ncbi.nlm.nih.gov/pubmed/31371645 http://dx.doi.org/10.1136/jnnp-2019-321073 |
Ejemplares similares
-
Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia
por: van der Ende, Emma L, et al.
Publicado: (2020) -
Imaging and CSF analyses effectively distinguish CJD from its mimics
por: Rudge, Peter, et al.
Publicado: (2018) -
Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal dementia and amyotrophic lateral sclerosis
por: Wilson, Katherine M, et al.
Publicado: (2022) -
Posiphen as a candidate drug to lower CSF amyloid precursor protein, amyloid-β peptide and τ levels: target engagement, tolerability and pharmacokinetics in humans
por: Maccecchini, Maria L, et al.
Publicado: (2012) -
Blood Kallikrein-8 and Non-Amnestic Mild Cognitive Impairment: An Exploratory Study
por: Schramm, Sara, et al.
Publicado: (2023)